Media headlines about DURECT (NASDAQ:DRRX) have trended somewhat positive on Tuesday, Accern Sentiment reports. The research group scores the sentiment of media coverage by reviewing more than twenty million news and blog sources in real time. Accern ranks coverage of public companies on a scale of negative one to one, with scores nearest to one being the most favorable. DURECT earned a media sentiment score of 0.13 on Accern’s scale. Accern also assigned media coverage about the specialty pharmaceutical company an impact score of 46.8128374564892 out of 100, meaning that recent media coverage is somewhat unlikely to have an effect on the company’s share price in the next several days.
Several brokerages recently weighed in on DRRX. ValuEngine raised DURECT from a “sell” rating to a “hold” rating in a report on Tuesday, September 26th. Stifel Nicolaus lowered DURECT from a “buy” rating to a “hold” rating in a report on Friday, October 20th. HC Wainwright lowered DURECT from a “buy” rating to a “neutral” rating and set a $3.00 price target on the stock. in a research note on Friday, October 20th. Finally, Laidlaw lowered their price target on DURECT from $3.00 to $2.00 and set a “buy” rating on the stock in a research note on Friday, October 20th.
DURECT (NASDAQ:DRRX) remained flat at $$1.08 during midday trading on Tuesday. The company’s stock had a trading volume of 445,600 shares, compared to its average volume of 722,158. The company has a debt-to-equity ratio of 1.46, a quick ratio of 1.57 and a current ratio of 1.67. DURECT has a 52 week low of $0.74 and a 52 week high of $2.17.
DURECT (NASDAQ:DRRX) last released its quarterly earnings data on Wednesday, November 1st. The specialty pharmaceutical company reported $0.04 earnings per share for the quarter, topping the Zacks’ consensus estimate of ($0.05) by $0.09. DURECT had a negative return on equity of 419.65% and a negative net margin of 62.57%. The company had revenue of $20.75 million for the quarter, compared to analyst estimates of $5.09 million. equities analysts forecast that DURECT will post -0.14 EPS for the current fiscal year.
ILLEGAL ACTIVITY NOTICE: “DURECT (NASDAQ:DRRX) Earns Media Impact Rating of 0.13” was reported by Dispatch Tribunal and is the sole property of of Dispatch Tribunal. If you are viewing this piece on another domain, it was copied illegally and republished in violation of United States & international copyright & trademark law. The correct version of this piece can be accessed at https://www.dispatchtribunal.com/2017/12/05/durect-corporation-drrx-receives-daily-news-impact-rating-of-0-13.html.
DURECT Company Profile
Durect Corporation is a biopharmaceutical company with research and development programs. The Company’s products candidates include DUR-928, oral for metabolic/lipid disorders, and DUR-928, injectable for acute organ injuries. Its other product candidates include POSIMIR (controlled release injection of bupivacaine), REMOXY (oral controlled release oxycodone), ORADUR-ADHD, ELADUR (controlled release injection of bupivicane), Relday (risperidone), ORADUR-based opioid (hydromorphone) and SABER-based ophthalmic.
Receive News & Ratings for DURECT Corporation Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for DURECT Corporation and related companies with MarketBeat.com's FREE daily email newsletter.